Fact Check: Did FDA Approve Galleri After the Advisory Vote? No

The claim and verdict

Claims that the Food and Drug Administration approved Galleri after a September 23 advisory committee vote are false. The panel recommended that the test's benefits outweigh its risks, but the FDA has not issued the final premarket approval decision.

Reuters reported that panel members voted 10–0 that Galleri is reasonably safe, 6–4 that it is effective and 7–2, with one abstention, that its benefits outweigh its risks. The split effectiveness vote is part of the public record; it should not be flattened into a claim of unanimous endorsement.

FDA's meeting page states that advisory committees provide independent expert advice and make nonbinding recommendations. The agency generally follows such recommendations but is not legally required to do so. A recommendation and an approval are separate regulatory events.

What the application asks FDA to authorize

GRAIL's premarket approval application describes Galleri as a prescription-only blood test for adults 50 and older. It analyzes cell-free DNA for cancer-associated methylation patterns and, after a cancer signal is detected, predicts where that signal may have originated.

The proposed use does not turn the test into a diagnosis. FDA's voting document says a detected signal should be followed by diagnostic workup by qualified health professionals. It also says that a result finding no cancer signal does not rule out cancer.

Galleri is currently offered through GRAIL's CLIA-certified laboratory. The company's own disclosure says the test has not been cleared or approved by FDA. Laboratory availability under CLIA does not answer the different question now before FDA in the PMA review.

The vote numbers show where uncertainty remains

Safety received ten yes votes and no no votes. Effectiveness received six yes and four no votes, a two-vote margin. The overall benefit-risk question received seven yes votes, two no votes and one abstention. Those three questions measure different parts of the statutory decision, so the strongest vote cannot be substituted for the closest one.

FDA's executive summary says the application was submitted January 29, 2026, and that the agency sought expert input on whether evidence from PATHFINDER 2 and NHS-Galleri shows that probable benefits outweigh probable risks. The summary also warns that it may not contain all evidence relevant to the final regulatory recommendation.

What patients should do while the decision is pending

FDA's proposed limitations explicitly say Galleri is not a replacement for existing single-cancer screening or diagnostic methods. That guidance remains important regardless of the eventual PMA decision.

The accurate status is therefore: an expert panel recommended approval on balance, with a divided effectiveness vote; FDA's own decision remains pending.

• Do not treat the panel vote as an FDA approval notice; look for a final FDA order and approved labeling.
• Do not replace recommended mammography, colorectal, cervical, lung or prostate screening with Galleri.
• Discuss both false-positive and false-negative possibilities with a clinician before ordering the test.
• If a cancer signal is detected, follow through with the diagnostic evaluation recommended by a qualified professional.